These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2064423)

  • 1. [Prognostic markers in transitional carcinoma of the bladder].
    Blasco E; Gutiérrez-Hoyos A; Garrido C; Arozena F
    Arch Esp Urol; 1991; 44(1):47-52. PubMed ID: 2064423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of the Thomsen-Friedenreich antigen in bladder tumors].
    Fukatsu H; Yamada H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Nishikawa E; Yamada Y
    Hinyokika Kiyo; 1988 Feb; 34(2):260-7. PubMed ID: 3376818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor.
    Summers JL; Coon JS; Ward RM; Falor WH; Miller AW; Weinstein RS
    Cancer Res; 1983 Feb; 43(2):934-9. PubMed ID: 6848204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
    Igawa M
    Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low-grade and low-stage transitional carcinoma of the bladder. Review].
    Escudero Barrilero A; Gutiérrez Sanz Gadea C; Hernández Fernández C; Romero Maroto J; Tallada Buñuel M; Perales Cabanas L
    Actas Urol Esp; 1985; 9(3):203-8. PubMed ID: 3898736
    [No Abstract]   [Full Text] [Related]  

  • 6. c-erbB-2 gene product-like expression in urothelial carcinomas of the human bladder. Its value as a prognostic indicator in superficial tumors.
    Serio G
    Pathologica; 1991; 83(1086):413-20. PubMed ID: 1686491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The usefulness of the carbohydrate antigen CA-50 in the prognosis of transitional-cell bladder carcinomas].
    Moreno Sierra J; Blanco Jímenez E; Silmi Moyano A; Ortega Heredia MD; Páramo González P; Maestro de las Casas ML; Fernández Lucas C; Ramírez Fernández JC; Luengo Alpuente S; Gómez Vegas A
    Arch Esp Urol; 1993 Nov; 46(9):775-8. PubMed ID: 8304791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent diagnostic modalities for bladder cancer.
    Sheinfeld J; Cordon-Cardo C; Bander NH
    Immunol Ser; 1990; 53():485-97. PubMed ID: 2151621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivariate analysis DNA/cytokeratin 7 and flow cytometric measurement of MIB-1 in superficial transitional carcinoma of the bladder (TCC). Methodological aspects and prognostic implications.
    Leonardi E; Cristofori A; Reich A; Dalla Palma P
    Eur J Histochem; 1997; 41 Suppl 2():133-4. PubMed ID: 9859817
    [No Abstract]   [Full Text] [Related]  

  • 10. Markers of prognosis in superficial bladder cancer.
    Fradet Y
    Semin Urol; 1992 Feb; 10(1):28-38. PubMed ID: 1565901
    [No Abstract]   [Full Text] [Related]  

  • 11. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors and markers used in urothelial carcinoma of the bladder].
    Billerey C; Vieillefond A
    Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study.
    Juhl BR
    Dan Med Bull; 1994 Feb; 41(1):1-11. PubMed ID: 8187557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple cell markers in bladder cancer. Principles and clinical applications.
    Javadpour N
    Urol Clin North Am; 1984 Nov; 11(4):609-16. PubMed ID: 6390912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular F-actin levels as a marker for cellular transformation: correlation with bladder cancer risk.
    Rao JY; Hemstreet GP; Hurst RE; Bonner RB; Min KW; Jones PL
    Cancer Res; 1991 Jun; 51(11):2762-7. PubMed ID: 2032215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
    Pantazopoulos D; Ioakim-Liossi A; Karakitsos P; Aroni K; Kakoliris S; Kanavaros P; Kyrkou KA
    Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis.
    Malmström PU
    Scand J Urol Nephrol Suppl; 1988; 112():1-55. PubMed ID: 3068792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell lines.
    Brockhoff G; Hofstaedter F; Knuechel R
    Cytometry; 1994 Sep; 17(1):75-83. PubMed ID: 8001460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometry and prognostic implications in patients with solid tumors.
    Williams NN; Daly JM
    Surg Gynecol Obstet; 1990 Sep; 171(3):257-66. PubMed ID: 2201096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.